Dr. Shashi Gujar of Dal’s Department of Pathology. (File photo)

Repurposing COVID-19 immune response for cancer therapy

Posted on

COVID-19 has touched almost every country around the world since it emerged months ago. As of September 9, 2020, 27.6 million people have been infected with the SARS-CoV-2 virus, and there have been 898,000 deaths. But, a Dal scientist is hoping that there is a silver lining to this catastrophic pandemic.

Dr. Shashi Gujar, a scientist with the Department of Pathology at Dal, together with partners in France, Demark, Germany, the United States and India, is examining whether the immune response to SARS-CoV-2 could be repurposed as the next generation of cancer immunotherapy…..

https://www.dal.ca/news/2020/09/14/repurposing-covid-19-immune-response-for-cancer-therapy.html

Read More Impact Stories

Posted on
McGill-developed device offers 100 per cent accuracy in as little as 10 minutes, and can be configured to detect a [...]
Posted on
This content is available in French only.
Posted on
The University of Toronto and Moderna, Inc. known for its mRNA-based COVID-19 vaccine plan to work together to develop new [...]